PXK: A Potential Drug Target for Cancer Treatment (G54899)

Target Name: PXK

NCBI ID: G54899

Content of Review Report on PXK Target / Biomarker

PXK

PXK: A Potential Drug Target for Cancer Treatment

PXK (Promyelocytic leukemia kinase), also known as MONAKA, is a protein that is expressed in various tissues of the body, including the brain, spleen, and peripheral blood cells. It is a key regulator of the cell cycle, and is involved in the development and progression of many types of cancer.

Recent studies have identified PXK as a potential drug target and biomarker for the treatment of various diseases, including cancer.

One of the key reasons for the interest in PXK is its role in the regulation of the cell cycle. The cell cycle is the process by which a cell grows, replicates its DNA, and divides. PXK is involved in the regulation of the length and timing of cell cycles, which is critical for the growth and development of cancer cells.

In addition, PXK is also known to play a role in the regulation of cell survival. Studies have shown that PXK can inhibit the ability of cancer cells to divide and can also induce cell apoptosis (programmed cell death), which may be a potential mechanism of cancer treatment.

Another potential mechanism by which PXK may be involved in cancer treatment is its role in the development of resistance to chemotherapy. Many cancer cells develop resistance to chemotherapy, which can make the treatment more difficult and effective. PXK has been shown to play a role in the development of resistance in various types of cancer.

In addition to its potential as a drug target and biomarker, PXK is also of interest as a potential therapeutic approach for the treatment of certain types of cancer. For example, PXK has been shown to be downregulated in many types of cancer, including leukemia and lymphoma. Therefore, targeting PXK with drugs or other therapeutic approaches may be a potential strategy for the treatment of these diseases.

Overall, PXK is a protein that has significant implications for the development and treatment of cancer. Further research is needed to fully understand its role in the regulation of the cell cycle and its potential as a drug target and biomarker.

Protein Name: PX Domain Containing Serine/threonine Kinase Like

Functions: Binds to and modulates brain Na,K-ATPase subunits ATP1B1 and ATP1B3 and may thereby participate in the regulation of electrical excitability and synaptic transmission. May not display kinase activity

The "PXK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PXK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets